Hengrui Pharmaceutical announced that its subsidiary Suzhou Shengdia Biomedical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for injectable carelizumab and will conduct clinical trials in the near future.
恒瑞医药：注射用卡瑞利珠单抗收到药物临床试验批准通知书
Hengrui Pharmaceutical: injectable carelizumab received a notice of approval for clinical trials of the drug
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.